•
Mar 31, 2021

Globus Medical Q1 2021 Earnings Report

Globus Medical's Q1 2021 financial performance was announced, demonstrating substantial growth in net sales and net income.

Key Takeaways

Globus Medical reported a strong start to 2021 with a 19.3% increase in worldwide net sales, reaching $227.3 million. GAAP net income increased by 74.7% to $45.3 million, and non-GAAP adjusted EBITDA reached $81.0 million, marking 35.2% of net sales.

Worldwide net sales increased by 19.3% compared to Q1 2020, totaling $227.3 million.

GAAP net income rose by 74.7% to $45.3 million, representing 19.9% of net sales.

GAAP diluted EPS was $0.44, and non-GAAP diluted EPS was $0.49.

Non-GAAP adjusted EBITDA was $81.0 million, accounting for 35.2% of net sales.

Total Revenue
$227M
Previous year: $191M
+19.3%
EPS
$0.49
Previous year: $0.29
+69.0%
Adjusted EBITDA as % of sales
80,126,000%
Previous year: 26.5%
+302362164.2%
Gross Profit
$172M
Previous year: $142M
+21.6%
Cash and Equivalents
$185M
Previous year: $167M
+10.9%
Free Cash Flow
$49.9M
Previous year: $20M
+149.8%
Total Assets
$1.74B
Previous year: $1.48B
+17.5%

Globus Medical

Globus Medical

Globus Medical Revenue by Segment

Globus Medical Revenue by Geographic Location

Forward Guidance

The company increased full year 2021 net sales guidance from $880 million to $925 million and non-GAAP diluted earnings per share guidance from $1.83 to $1.89.

Revenue & Expenses

Visualization of income flow from segment revenue to net income